EP2863897A4 - Nanoparticles of indirubin, derivatives thereof and methods of making and using same - Google Patents
Nanoparticles of indirubin, derivatives thereof and methods of making and using sameInfo
- Publication number
- EP2863897A4 EP2863897A4 EP13806153.6A EP13806153A EP2863897A4 EP 2863897 A4 EP2863897 A4 EP 2863897A4 EP 13806153 A EP13806153 A EP 13806153A EP 2863897 A4 EP2863897 A4 EP 2863897A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- indirubin
- nanoparticles
- derivatives
- making
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 title 2
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 title 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19180122.4A EP3597178A1 (en) | 2012-06-21 | 2013-06-21 | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662469P | 2012-06-21 | 2012-06-21 | |
PCT/US2013/046981 WO2013192493A1 (en) | 2012-06-21 | 2013-06-21 | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19180122.4A Division EP3597178A1 (en) | 2012-06-21 | 2013-06-21 | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2863897A1 EP2863897A1 (en) | 2015-04-29 |
EP2863897A4 true EP2863897A4 (en) | 2016-01-27 |
EP2863897B1 EP2863897B1 (en) | 2019-06-19 |
Family
ID=49769412
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19180122.4A Withdrawn EP3597178A1 (en) | 2012-06-21 | 2013-06-21 | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
EP13806153.6A Active EP2863897B1 (en) | 2012-06-21 | 2013-06-21 | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19180122.4A Withdrawn EP3597178A1 (en) | 2012-06-21 | 2013-06-21 | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
Country Status (6)
Country | Link |
---|---|
US (3) | US10039829B2 (en) |
EP (2) | EP3597178A1 (en) |
JP (5) | JP6382187B2 (en) |
CN (2) | CN110123763A (en) |
CA (1) | CA2914782C (en) |
WO (1) | WO2013192493A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6382187B2 (en) * | 2012-06-21 | 2018-08-29 | フォスフォレックス,インコーポレーテッド | Nanoparticles of indirubin, their derivatives and methods for making and using them |
CN106029065A (en) * | 2013-12-20 | 2016-10-12 | 法斯瑞斯公司 | Indirubin solid dispersion composition |
RU2630561C2 (en) * | 2015-10-20 | 2017-09-11 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России | Method for production of fullerene water-salt dispersions |
WO2018183631A1 (en) * | 2017-03-29 | 2018-10-04 | Phosphorex, Inc. | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same |
RU2721318C1 (en) * | 2019-02-28 | 2020-05-18 | Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" | Method of producing sols and suspensions |
CN114340600A (en) * | 2019-05-03 | 2022-04-12 | 阿佐拉治疗股份有限公司 | Compositions comprising indigo and/or indigo derivatives and methods of use thereof |
CN114668744A (en) * | 2022-03-23 | 2022-06-28 | 成都大学 | Indirubin solid lipid nanoparticle and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051900A1 (en) * | 2001-12-13 | 2003-06-26 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
CN1615852A (en) * | 2003-11-10 | 2005-05-18 | 许军 | Indirubin oral dripping pill and preparing process |
CN101362066A (en) * | 2008-09-27 | 2009-02-11 | 同济大学 | Preparation method of liposome embedded quantum dots silicon dioxide microspheres and products thereof |
CN101775082A (en) * | 2010-02-09 | 2010-07-14 | 中国药科大学 | Amphoteric ion-based charge reversal chitosan derivative and application thereof in medicament |
CN102228433A (en) * | 2011-06-29 | 2011-11-02 | 上海中医药大学 | Supersaturated self-microemulsion as well as preparation method and application thereof |
CN102018736B (en) * | 2010-11-19 | 2012-03-28 | 成都中医药大学 | Natural indigo decoction piece and preparation method thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4929242A (en) * | 1986-11-26 | 1990-05-29 | Baxter International Inc. | Solution and method for maintaining patency of a catheter |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
DE10129028A1 (en) * | 2001-06-11 | 2003-01-02 | Schering Ag | Soluble Cdk-inhibitory Indirubin Derivatives |
US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
AU2003230691A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
US7230005B2 (en) * | 2003-03-13 | 2007-06-12 | Controlled Chemicals, Inc. | Compounds and methods for lowering the abuse potential and extending the duration of action of a drug |
KR100588803B1 (en) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | Indirubin derivatives having anticancer property against human cancer cell line |
UA89513C2 (en) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Nanoparticulate raloxifene hydrochloride composition |
JP2008524239A (en) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | Nanoparticulate tacrolimus formulation |
US20060159767A1 (en) * | 2004-12-22 | 2006-07-20 | Elan Pharma International Limited | Nanoparticulate bicalutamide formulations |
CN101132770A (en) * | 2005-01-06 | 2008-02-27 | 伊兰制药国际有限公司 | Nanoparticulate candesartan formulations |
KR20080003322A (en) * | 2005-02-24 | 2008-01-07 | 엘란 파마 인터내셔널 리미티드 | Nanoparticulate formulations of docetaxel and analogues thereof |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
NZ561666A (en) * | 2005-03-17 | 2010-05-28 | Elan Pharma Int Ltd | Nanoparticulate biphosphonate compositions |
CN101180038A (en) * | 2005-03-23 | 2008-05-14 | 伊兰制药国际有限公司 | Nanoparticulate corticosteroid and antihistamine formulations |
CN101198314A (en) * | 2005-04-12 | 2008-06-11 | 伊兰制药国际有限公司 | Nanoparticulate quinazoline derivative formulations |
MX2007012762A (en) * | 2005-04-12 | 2008-01-14 | Elan Pharma Int Ltd | Nanoparticulate and controlled release compositions comprising cyclosporine. |
US8158582B2 (en) | 2005-06-02 | 2012-04-17 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-1 deficiency |
CN101023944A (en) * | 2006-02-23 | 2007-08-29 | 黎明涛 | Use of indirubin derivative for preparing medicines for treating nerve retrograde affection |
CN101074229B (en) * | 2007-06-08 | 2010-09-01 | 无锡杰西医药科技有限公司 | 7-azaindirubin and 7-azaisoindigo derivative production and pharmaceutical use |
EP2057982A1 (en) | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
WO2009117042A1 (en) * | 2008-03-21 | 2009-09-24 | Adlyfe, Inc. | Use of pyrene to carry non-peptide agents across the blood brain barrier |
SI2113253T1 (en) | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
JP6382187B2 (en) * | 2012-06-21 | 2018-08-29 | フォスフォレックス,インコーポレーテッド | Nanoparticles of indirubin, their derivatives and methods for making and using them |
-
2013
- 2013-06-21 JP JP2015518599A patent/JP6382187B2/en active Active
- 2013-06-21 CA CA2914782A patent/CA2914782C/en active Active
- 2013-06-21 CN CN201910470369.1A patent/CN110123763A/en active Pending
- 2013-06-21 EP EP19180122.4A patent/EP3597178A1/en not_active Withdrawn
- 2013-06-21 CN CN201380043697.4A patent/CN104602675B/en active Active
- 2013-06-21 EP EP13806153.6A patent/EP2863897B1/en active Active
- 2013-06-21 WO PCT/US2013/046981 patent/WO2013192493A1/en active Application Filing
-
2014
- 2014-12-17 US US14/573,212 patent/US10039829B2/en active Active
-
2018
- 2018-07-20 US US16/040,640 patent/US10675350B2/en active Active
- 2018-08-01 JP JP2018144837A patent/JP2018199685A/en active Pending
-
2020
- 2020-01-09 JP JP2020001832A patent/JP2020073564A/en active Pending
-
2021
- 2021-07-19 JP JP2021118361A patent/JP2021181447A/en active Pending
- 2021-09-09 US US17/470,163 patent/US20220168423A1/en not_active Abandoned
-
2023
- 2023-02-15 JP JP2023021518A patent/JP2023062070A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051900A1 (en) * | 2001-12-13 | 2003-06-26 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
CN1615852A (en) * | 2003-11-10 | 2005-05-18 | 许军 | Indirubin oral dripping pill and preparing process |
CN101362066A (en) * | 2008-09-27 | 2009-02-11 | 同济大学 | Preparation method of liposome embedded quantum dots silicon dioxide microspheres and products thereof |
CN101775082A (en) * | 2010-02-09 | 2010-07-14 | 中国药科大学 | Amphoteric ion-based charge reversal chitosan derivative and application thereof in medicament |
CN102018736B (en) * | 2010-11-19 | 2012-03-28 | 成都中医药大学 | Natural indigo decoction piece and preparation method thereof |
CN102228433A (en) * | 2011-06-29 | 2011-11-02 | 上海中医药大学 | Supersaturated self-microemulsion as well as preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3597178A1 (en) | 2020-01-22 |
JP2020073564A (en) | 2020-05-14 |
US20220168423A1 (en) | 2022-06-02 |
US20190054174A1 (en) | 2019-02-21 |
US20150110878A1 (en) | 2015-04-23 |
JP2015520241A (en) | 2015-07-16 |
WO2013192493A1 (en) | 2013-12-27 |
US10039829B2 (en) | 2018-08-07 |
CN104602675B (en) | 2019-06-28 |
US10675350B2 (en) | 2020-06-09 |
JP6382187B2 (en) | 2018-08-29 |
CN110123763A (en) | 2019-08-16 |
EP2863897A1 (en) | 2015-04-29 |
JP2023062070A (en) | 2023-05-02 |
JP2018199685A (en) | 2018-12-20 |
EP2863897B1 (en) | 2019-06-19 |
CN104602675A (en) | 2015-05-06 |
CA2914782A1 (en) | 2013-12-27 |
JP2021181447A (en) | 2021-11-25 |
CA2914782C (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212977A1 (en) | Bendamustine derivatives and methods of using same | |
EP2895653A4 (en) | Method of producing dissolving pulp, dissolving pulp and use of method | |
IL238553B (en) | Substituted indol-5-ol derivatives, compositions comprising same and methods of producing same | |
ZA201404625B (en) | Polycyclic derivatives, preparation method and medical uses thereof | |
HK1204970A1 (en) | Polymer-agent conjugates, particles, compositions, and related methods of use | |
EP2822936A4 (en) | Aminoquinoline derivatives and uses thereof | |
EP2847254A4 (en) | Chemical modification of lignin and lignin derivatives | |
HRP20181704T1 (en) | Crystal form of chidamide, preparation method and use thereof | |
SG11201601047SA (en) | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | |
EP2863897A4 (en) | Nanoparticles of indirubin, derivatives thereof and methods of making and using same | |
EP2847255A4 (en) | Chemical modification of lignin and lignin derivatives | |
HK1198833A1 (en) | N-acylpeptide derivatives and their uses n- | |
IL229968A0 (en) | Tetrazolyloxime derivatives and methods of producing same | |
HK1204473A1 (en) | Methods of making and using nanostructures | |
EP2805956A4 (en) | Gambogenic acid derivatives, preparation method and application thereof | |
HK1216891A1 (en) | Bryoid compositions, methods of making and use thereof | |
IL234080A (en) | Tetrazolylhydroxyimino derivatives and methods for producing same | |
EP2870133A4 (en) | Tetrahydro-isohumulone derivatives, methods of making and using | |
HK1207313A1 (en) | Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same --25---25- | |
IL238934A0 (en) | Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of same | |
GB201206141D0 (en) | Method and uses for improved sowing of maize | |
AU2012903090A0 (en) | Compounds and methods of their use - IV | |
AU2012900650A0 (en) | Compounds and methods of their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150121 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20160108 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20151223BHEP Ipc: A61K 31/404 20060101ALI20151223BHEP Ipc: A61K 47/30 20060101ALI20151223BHEP Ipc: A61K 35/00 20060101ALI20151223BHEP Ipc: A61K 9/14 20060101ALI20151223BHEP Ipc: A61K 9/16 20060101AFI20151223BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180118 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20181128 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20190509 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013056868 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1144593 Country of ref document: AT Kind code of ref document: T Effective date: 20190715 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SERVOPATENT GMBH, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190919 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190919 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190920 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1144593 Country of ref document: AT Kind code of ref document: T Effective date: 20190619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191021 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191019 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190621 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013056868 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH) |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
26N | No opposition filed |
Effective date: 20200603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130621 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190619 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230528 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230620 Year of fee payment: 11 Ref country code: IE Payment date: 20230620 Year of fee payment: 11 Ref country code: FR Payment date: 20230620 Year of fee payment: 11 Ref country code: DE Payment date: 20230623 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230620 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602013056868 Country of ref document: DE Owner name: CYTODIGM, INC. (N.D.GES.D. STAATES DELAWARE), , US Free format text: FORMER OWNER: PHOSPHOREX, INC., HOPKINTON, MA, US |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20230620 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230620 Year of fee payment: 11 Ref country code: CH Payment date: 20230702 Year of fee payment: 11 |